BIAXIN XL
LOE ApproachingNDAORALTABLET
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BIAXIN XL is a macrolide antibiotic oral tablet approved in 1993 for bacterial infections. The extended-release formulation provides convenient once- or twice-daily dosing. It is used to treat respiratory tract infections, skin infections, and other bacterial conditions.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); smaller brand teams focus on volume retention and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BIAXIN XL offers limited upside given LOE-approaching lifecycle; roles focus on volume retention, generic transition planning, and cost management. Career advancement requires transition to growth-stage products or shift to generic/biosimilar operational roles.
Brand ManagerField Sales Representative
Worked on BIAXIN XL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.